Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02XTT
|
|||
| Former ID |
DIB006730
|
|||
| Drug Name |
LV305
|
|||
| Synonyms |
NY-ESO-1 Zvex
Click to Show/Hide
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 1 | [1] | |
| Melanoma [ICD-11: 2C30] | Phase 1 | [1] | ||
| Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 1 | [1] | ||
| Company |
Immune design
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02122861) A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.